Cellular delivery of doxorubicin via pH-controlled hydrazone linkage using multifunctional nano vehicle based on poly(β-L-malic acid)

International Journal of Molecular Sciences

Volumn 13, Issue 9, 2012, Pages 11681-11693

  Patil, Rameshwar ^a   Portilla Arias, Jose ^a   Ding, Hui ^a   Konda, Bindu ^a   Rekechenetskiy, Arthur ^a   Inoue, Satoshi ^a   Black, Keith L ^a   Holler, Eggehard ^a,b   Ljubimova, Julia Y ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Brain and breast cancer; Doxorubicin; Nanoconjugate; pH controlled hydrazine linkage; Polymalic acid

Indexed keywords

DOXORUBICIN; HYDRAZONE DERIVATIVE; MACROGOL; MALIC ACID DERIVATIVE; NANOCARRIER; NANOCONJUGATE; POLY(BETA MALIC ACID); UNCLASSIFIED DRUG;

ARTICLE; BIODEGRADABILITY; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG RELEASE; DRUG STRUCTURE; ENDOSOME; GLIOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; LYSOSOME; PH; PRIMARY TUMOR;

EID: 84866887465     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms130911681     Document Type: Article

References (42)

1. Wiernik, P.H.; Dutcher, J.P. Clinical importance of anthracyclines in the treatment of acute myeloid leukemia. Leukemia 1992, 6, 67-69.
2. Lown, J.W. Anthracycline and anthraquinone anticancer agents: Current status and recent developments. Pharmacol. Ther. 1993, 60, 185-214.
3. Gottesman, M.M.; Pastan, I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 1993, 62, 385-427.
4. Germann, U.A. P-Glycoprotein-A mediator of multidrug resistance in tumour cells. Eur. J. Cancer 1996, 32A, 927-944.
5. Borst, P.; Evers, R.; Kool, M.; Wijnholds, J. A family of drug transporters: The multidrug resistance-associated proteins. J. Natl. Cancer Inst. 2000, 92, 1295-1302.
6. Marie, J.P.; Zhou, D.C.; Gurbuxani, S.; Legrand, O.; Zittoun, R. MDR1/P-Glycoprotein in haematological neoplasms. Eur. J. Cancer 1996, 32A, 1034-1038.
7. Kopecek, J.; Kopeckova, P.; Minko, T.; Lu, Z. HPMA copolymer-anticancer drug conjugates: Design, Activity, and mechanism of action. Eur. J. Pharm. Biopharm. 2000, 50, 61-81.
8. Seymour, L.W.; Ulbrich, K.; Steyger, P.S.; Brereton, M.; Subr, V.; Strohalm, J.; Duncan, R. Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma. Br. J. Cancer 1994, 70, 636-641.
9. Rihova, B.; Bilej, M.; Vetvicka, V.; Ulbrich, K.; Strohalm, J.; Kopecek, J.; Duncan, R. Biocompatibility of N-(2-Hydroxypropyl) methacrylamide copolymers containing adriamycin: Immunogenicity, and effect on haematopoietic stem cells in bone marrow in vivo and mouse splenocytes and human peripheral blood lymphocytes in vitro. Biomaterials 1989, 10, 335-342.
10. Rodrigues, P.C.; Beyer, U.; Schumacher, P.; Roth, T.; Fiebig, H.H.; Unger, C.; Messori, L.; Orioli, P.; Paper, D.H.; Mulhaupt, R. et al. Acid-Sensitive polyethylene glycol conjugates of doxorubicin: Preparation, in vitro efficacy and intracellular distribution. Bioorg. Med. Chem. 1999, 7, 2517-2524.
11. Ulbrich, K.; Etrych, T.; Chytil, P.; Jelinkova, M.; Rihova, B. HPMA copolymers with pH-controlled release of doxorubicin: In vitro cytotoxicity and in vivo antitumor activity. J. Control. Release 2003, 87, 33-47.
12. Nori, A.; Kopecek, J. Intracellular targeting of polymer-bound drugs for cancer chemotherapy. Adv. Drug Deliv. Rev. 2005, 57, 609-636.
13. Duncan, R.; Vicent, M.J.; Greco, F.; Nicholson, R.I. Polymer-Drug conjugates: Towards a novel approach for the treatment of endrocine-related cancer. Endocr. Related Cancer 2005, 12, S189-S199.
14. Maeda, H.; Fang, J.; Inutsuka, T.; Kitamoto, Y. Vascular permeability enhancement in solid tumor: Various factors, mechanisms involved and its implications. Int. Immunopharmacol. 2003, 3, 319-328.
15. Fujita, M.; Lee, B.S.; Khazenzon, N.M.; Penichet, M.L.; Wawrowsky, K.A.; Patil, R.; Ding, H.; Holler, E.; Black, K.L.; Ljubimova, J.Y. Brain tumor tandem targeting using a combination of monoclonal antibodies attached to Biopoly(β-L-Malic Acid). J. Control. Release 2007, 122, 356-363.
16. Lee, B.S.; Fujita, M.; Khazenzon, N.M.; Wawrowsky, K.A.; Wachsmann-Hogiu, S.; Farkas, D.L.; Black, K.L.; Ljubimova, J.Y.; Holler, E. Polycefin, a new prototype of a multifunctional nanoconjugate based on Poly(β-L-Malic Acid) for drug delivery. Bioconjug. Chem. 2006, 17, 317-326.
17. Segal, E.; Satchi-Fainaro, R. Design and development of polymer conjugates as anti-angiogenic agents. Adv. Drug Deliv. Rev. 2009, 61, 1159-1176.
18. Peer, D.; Karp, J.M.; Hong, S.; Farokhzad, O.C.; Margalit, R.; Langer, R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2007, 2, 751-760.
19. Ferrari, M. Cancer nanotechnology: Opportunities and challenges. Nat. Rev. Cancer 2005, 5, 161-171.
20. Duncan, R. The dawning era of polymer therapeutics. Nat. Rev. Drug Discov. 2003, 2, 347-360.
21. Vinogradov, S.V.; Batrakova, E.V.; Li, S.; Kabanov, A.V. Mixed polymer micelles of amphiphilic and cationic copolymers for delivery of antisense oligonucleotides. J. Drug Target. 2004, 12, 517-526.
22. Kabanov, A.V.; Batrakova, E.V.; Sriadibhatla, S.; Yang, Z.; Kelly, D.L.; Alakov, V.Y. Polymer genomics: Shifting the gene and drug delivery paradigms. J. Control. Release 2005, 101, 259-271.
23. Barenholz, Y. Doxil®-The first fda-approved nano-drug: Lessons learned. J. Control. Release 2012, 160, 117-134.
24. Ulbrich, K.; Etrych, T.; Chytil, P.; Jelinkova, M.; Rihova, B. Antibody-targeted polymer-doxorubicin conjugates with pH-controlled activation. J. Drug Target. 2004, 12, 477-489.
25. Lee, C.C.; Gillies, E.R.; Fox, M.E.; Guillaudeu, S.J.; Frechet, J.M.; Dy, E.E.; Szoka, F.C. A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas. Proc. Natl. Acad. Sci. USA 2006, 103, 16649-16654.
26. Patil, R.; Portilla-Arias, J.; Ding, H.; Inoue, S.; Konda, B.; Hu, J.; Wawrowsky, K.A.; Shin, P.K.; Black, K.L.; Holler, E. et al. Temozolomide delivery to tumor cells by a multifunctional nano vehicle based on Poly(β-L-Malic Acid). Pharm. Res. 2010, 27, 2317-2329.
27. Ding, H.; Inoue, S.; Ljubimov, A.V.; Patil, R.; Portilla-Arias, J.; Hu, J.; Konda, B.; Wawrowsky, K.A.; Fujita, M.; Karabalin, N. et al. Inhibition of brain tumor growth by intravenous Poly(β-L-Malic Acid) nanobioconjugate with pH-Dependent drug release. Proc. Natl. Acad. Sci. USA 2010, 107, 18143-18148.
28. Inoue, S.; Ding, H.; Portilla-Arias, J.; Hu, J.; Konda, B.; Fujita, M.; Espinoza, A.; Suhane, S.; Riley, M.; Gates, M. et al. Polymalic acid-based nanobiopolymer provides efficient systemic breast cancer treatment by inhibiting both Her2/Neu receptor synthesis and activity. Cancer Res. 71, 1454-1464.
29. Inoue, S.; Patil, R.; Portilla-Arias, J.; Ding, H.; Konda, B.; Espinoza, A.; Mongayt, D.; Markman, J.L.; Elramsisy, A.; Phillips, H.W. et al. Nanobiopolymer for direct targeting and inhibition of EGFR expression in triple negative breast cancer. PLoS One 2012, 7, e31070.
30. Coessens, V.; Schacht, E.; Domurado, D. Synthesis of polyglutamine and dextran conjugates of streptomycin with an acid-sensitive drug-carrier linkage. J. Control. Release 1996, 38, 141-150.
31. Liu, Q.; Li, R.T.; Qian, H.Q.; Yang, M.; Zhu, Z.S.; Wu, W.; Qian, X.P.; Yu, L.X.; Jiang, X.Q.; Liu, B.R. Gelatinase-Stimuli Strategy enhances the tumor delivery and therapeutic efficacy of docetaxel-loaded Poly(Ethylene Glycol)-Poly(Varepsilon-Caprolactone) nanoparticles. Int. J. Nanomed. 2012, 7, 281-295.
32. Wang, H.; Zhao, Y.; Wu, Y.; Hu, Y.L.; Nan, K.; Nie, G.; Chen, H. Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles. Biomaterials 2011, 32, 8281-8290.
33. Zhang, L.; Hu, Y.; Jiang, X.; Yang, C.; Lu, W.; Yang, Y.H. Camptothecin derivative-loaded Poly(Caprolactone-Co-Lactide)-b-PEG-b-Poly(Caprolactone-Co-Lactide) nanoparticles and their biodistribution in mice. J. Control. Release 2004, 96, 135-148.
34. Wong, E.T.; Yamaguchi, N.H. Treatment advances for glioblastoma. Expert Rev. Neurother. 2011, 11, 1343-1345.
35. Madhankumar, A.B.; Slagle-Webb, B.; Mintz, A.; Sheehan, J.M.; Connor, J.R. Interleukin-13 receptor-targeted nanovesicles are a potential therapy for glioblastoma multiforme. Mol. Cancer Ther. 2006, 5, 3162-3169.
36. Bolhuis, H.; van Veen, H.W.; Poolman, B.; Driessen, A.J.; Konings, W.N. Mechanisms of multidrug transporters. FEMS Microbiol. Rev. 1997, 21, 55-84.
37. Martin, V.; Xu, J.; Pabbisetty, S.K.; Alonso, M.M.; Liu, D.; Lee, O.H.; Gumin, J.; Bhat, K.P.; Colman, H.; Lang, F.F. et al. Tie2-Mediated multidrug resistance in malignant gliomas is associated with upregulation of ABC transporters. Oncogene 2009, 28, 2358-2363.
38. Yap, T.A.; Workman, P. Exploiting the cancer genome: Strategies for the discovery and clinical development of targeted molecular therapeutics. Annu. Rev. Pharmacol. Toxicol. 2012, 52, 549-573.
39. Holler, E. Poly(malic Acid) from Natural Sources. In Handbook of Engineering Polymeric Materials; Marcel Dekker: New York, NY, USA, 1997; Volume 997, pp. 93-103.
40. Hiemenz, P.C. Light Scattering by Polymer Solutions. In Polymer Chemistry: The Basic Concepts; Marcel Decker Inc.: New York, NY, USA, 1984; pp. 659-719.
41. International Organization for Standardization (ISO). Methods for Determination of Particle Size Distribution Part 8: Photon Correlation Spectroscopy. International Standard ISO 13321, ISO: Geneva, Switzerland, 1996.
42. Mosmann, T.J. Rapid colorimetric assays for cellular growth and survival: Application to proliferation and cytotoxicity assays. Immunol. Methods 1983, 65, 55-63.